Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

Fulcrum Therapeutics starts strategic review for sale after FDA blocks pociredir for sickle cell disease; stock down 50%. FDA's hard stance on PRC2 inhibitors signals market consolidation: Pfizer and Novartis already withdrew therapies, indicating survival only for large pharma.